جست‌وجوی استاد و پژوهشگر

Caroline Samerمشاهده پروفایل

دانشیار

• Pharmacogenomics
• Precision Medicine
• Clinical Pharmacology
• +۳ مورد دیگر

Caroline Samer is an Associate Professor at the University of Geneva (UNIGE) Faculty of Medicine and serves as the Head of the Division of Clinical Pharmacology and Toxicology at the Hôpitaux Universitaires de Genève (HUG) . She also acts as the Delegate to the Dean's Office for Data Issues since July 2023. Medical Degree (2001), PhD in Pharmacogenomics, Postdoctoral Fellowship in Molecular Pharmacology (Sydney) President of the Swiss Society for Clinical Pharmacology and Toxicology (SSPTC) and Swiss Society of Pharmacology and Toxicology (SSPT) Vice-President of Swissethics and the Geneva Research Ethics Committee (CCER) Her research focuses on personalizing drug therapy through pharmacogenomics and precision medicine , emphasizing gene-environment-disease interactions and omic technologies . Key themes include drug interactions , pharmacokinetic modeling , and therapeutic information . Recent publications highlight her work in pharmacogenomics , drug safety , and clinical pharmacology , with a focus on opioids , antiaggregants , and drug metabolism . Her collaborations span oncopediatrics , internal medicine , medical informatics , and pharmaceutical sciences . She leads the Samer-Daali Research Group , which integrates in vitro , in vivo , and in silico models to advance personalized therapy . Her work is supported by institutional affiliations with the Faculty Center of Translational Investigation in Biomarkers and CIOMS .

Marc Schneiderمشاهده پروفایل

استاد

• Colloidal drug delivery systems
• Nanoparticle and microparticle engineering
• Nanotechnology in pharmacy
• +۳ مورد دیگر

Prof. Dr. Marc Schneider holds a professorship in Biopharmaceutics and Pharmaceutical Technology at Saarland University's College of Pharmacy . His research focuses on colloidal drug delivery systems, particularly nanostructured and non-spherical particle engineering for overcoming biological barriers in pulmonary and transdermal applications. He leads an internationally recognized lab in Saarbrücken, collaborating with Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and trinational institutions. Research Highlights: Development of inhalable nano/microparticle systems Surface modification of gelatin nanoparticles Characterization of mucus-penetrating particles 3D printing for microneedle fabrication Atomic Force Microscopy (AFM) for nanoparticle analysis Selected Scientific Awards: European Journal of Pharmaceutics and Biopharmaceutics Best Paper Award (2018) for mucus-penetrating nanoparticles Recognized in 'Ausgezeichnete Orte im Land der Ideen' competition (2018) for 'Nano-Mais' drug delivery system Collaborative Networks: Co-editor for Advanced Drug Delivery Reviews special issue on biological barriers Key participant in trinational Master's program in Biomedicine with Strasbourg, Mainz, and Luxembourg Active in Controlled Release Society (CRS) conferences and local chapters

Allan Davidمشاهده پروفایل

استاد

• Smart Materials
• Nanomedicine
• Cancer Research
• +۴ مورد دیگر

Allan David serves as the John W. Brown Professor of Chemical Engineering and Associate Dean for Research at Auburn University's Samuel Ginn College of Engineering. His leadership extends across academic administration and cutting-edge nanomedicine research, with a focus on translating laboratory discoveries into clinical applications. His educational foundation includes: Ph.D. in Chemical Engineering, University of Maryland B.S. in Chemical Engineering, University of Maryland Dr. David's research program pioneers nanomedicine applications through the development of smart materials for cancer diagnostics and therapy. His work spans nanoparticle-based MRI contrast agents , ocular drug delivery systems , and vaccine delivery platforms , with particular emphasis on optimizing physicochemical properties for targeted biological interactions. Current projects address critical healthcare challenges including safer contrast agents for patients with kidney impairment and precision cancer targeting mechanisms. Analysis of his 15 most recent publications reveals a cohesive research trajectory centered on magnetic nanoparticles and biomimetic delivery systems . The work demonstrates increasing translational focus, evolving from fundamental nanoparticle characterization (2020-2021) to clinically relevant applications like ocular delivery and cancer theranostics (2022-2024), culminating in commercialization efforts through NanoXort, LLC. Dr. David has secured significant research funding including an $184,773 grant from the Alabama Department of Economic and Community Affairs (ADECA) for developing cardiovascular MRI agents. He leads collaborative efforts that bridge chemical engineering with biomedical innovation, notably co-founding NanoXort, LLC to commercialize safer MRI contrast agents addressing gadolinium toxicity concerns for renal-impaired patients. His laboratory operates at the intersection of chemical engineering and medicine, focusing on nanoparticle-cell interactions and targeted delivery systems. The research group maintains strong industry partnerships through the NanoXort startup, which has secured $1 million NSF funding to advance MRI contrast agent technology toward clinical implementation.

• Antimicrobial Development
• Microbial Community Behavior
• Biofilm Research
• +۵ مورد دیگر

Hans Steenackers is an Associate Professor at the Faculty of Bioscience Engineering, KU Leuven, where he leads the MICA Lab within the Department of Microbial and Molecular Systems. His research focuses on innovative antimicrobial strategies targeting microbial communities, including socio-active, anti-resistance, and observation-guided approaches. Key research areas include biofilm dynamics antimicrobial resistance evolution in situ microbial monitoring Salmonella Typhimurium pathogenesis anti-virulence therapies His recent publications highlight advancements in biofilm inhibition, triggered antimicrobial release systems, and evolutionary robustness of probiotics. The majority of his work involves interdisciplinary collaborations, particularly in projects like TARDIS, ULTiMatE-MS, and MICROTUNe, with a focus on translating fundamental research into clinical applications. As an educator, he teaches advanced courses in microbial physiology, biofilm research, and applied biotechnology. The MICA Lab actively partners with academic and industrial stakeholders in initiatives such as the Flemish Scientific Research Network on Biofilms and the Bioclean H2020 project.

Yeonhwa Parkمشاهده پروفایل

استاد

• Functional Foods
• Obesity
• Environmental Contaminants
• +۳ مورد دیگر

Yeonhwa Park is a Professor and holder of the Francis Chair in the Department of Food Science at the University of Massachusetts Amherst. Her research focuses on functional foods, bioactive components, and environmental contaminants' effects on obesity and aging. She investigates food bioactives like conjugated linoleic acid (CLA) and environmental pollutants like PFAS to understand their roles in metabolic disorders and aging mechanisms. Her work spans multiple models, including C. elegans, zebrafish, and rodent studies, emphasizing translational applications for human health. Teaching responsibilities include courses such as 'Science of Food' (FS150), 'Biology of Food in Human Health' (FS270), and 'Bioactive Food Components' (FS750). Awards include Clarivate Highly Cited Researcher (2017–2018), Faculty Convocation Award (2015), and the Timothy Mounts Award (2015). Her research has been published in over 150 peer-reviewed articles, with recent emphasis on environmental contaminants' impact on obesity and type 2 diabetes, and the use of C. elegans for screening bioactives. Key findings include CLA's role in fat reduction, PFAS-induced metabolic disruption, and the application of alternative models (e.g., C. elegans) to reduce animal testing. Her lab integrates molecular biology, toxicology, and food science to address global health challenges like the obesity epidemic and environmental toxin exposure.

• Toxicology
• Environmental Toxicology
• Nanomaterial Toxicity
• +۳ مورد دیگر

Hans Bouwmeester is a Full Professor in Toxicology at Wageningen University & Research, specializing in chemical risk assessment, nanomaterial toxicity, and in vitro modeling. His work focuses on integrating artificial intelligence and physiologically based kinetic (PBK) models to predict toxic effects of contaminants like organophosphate pesticides, microplastics, and mycotoxins. He leads projects exploring the health impacts of foodborne contaminants in inflammatory bowel disease and developing animal-free testing methods. Key collaborations include EU initiatives like the ONTOX project and the GUTTEST program, which utilize advanced in vitro models such as gut-on-a-chip systems. Research interests span toxicokinetics, nanoplastics exposure, and the application of Bayesian networks for nanomaterial hazard ranking. His team addresses translational challenges in linking in vitro data to in vivo outcomes, with a focus on bile acid metabolism and cardiotoxicity prediction. Bouwmeester has supervised over 10 PhD candidates, including studies on microplastic hazard assessment, nanomaterial gastrointestinal fate, and AI-driven data extraction for risk assessment. Notable contributions include datasets on nanoplastics' protein corona effects and transcriptomic analyses of intestinal cell responses. His work is published in journals like Ecotoxicology and Environmental Safety , Toxicology , and Environmental Science & Technology , emphasizing open-access research and interdisciplinary approaches to chemical safety.

Ram Samudralaمشاهده پروفایل

استاد

• Bioinformatics
• Computational Biology
• Drug Discovery
• +۱۰ مورد دیگر

Ram Samudrala is a Professor and Chief of the Division of Bioinformatics at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences . His research focuses on multiscale computational biology , integrating protein structure prediction , drug discovery , and translational science to address medical challenges. He leads the development of the CANDO platform for therapeutic drug discovery and co-directs the Informatics Core at the Clinical and Translational Sciences Institute. PhD in Computational Biology (University of Maryland, 1997) BA in Computing Science and Genetics (Ohio Wesleyan University, 1993) Postdoctoral Fellowship in Protein Folding (Stanford University, 1997-2001) His work spans structural biology , genomics , and computational drug design , with applications in dentistry , infectious diseases , and cancer . He has received prestigious awards including the NIH Director's Pioneer Award (2010) and multiple Wiki Science Prizes . Samudrala's group collaborates globally, emphasizing in silico methods followed by in vitro and in vivo validation. Key grants include $1.22M NIH NCATS ASPIRE Reduction-to-Practice Award and $4.5M NIH/NLM BRIGHT Training Grant . 2023 Finalist, Clinical and Translational Sciences Institute Clinical Research Achievement Awards 2016 MacArthur Foundation 100&Change Top 50 2008 Alberta Heritage Foundation Visiting Scientist Award 2005 NSF CAREER Award He directs the BRIGHT Short-Term Training Program and serves on multiple editorial boards and review panels. Samudrala's group maintains a Protinfo web server for structural predictions and the Bioverse framework for systems-level analyses.

Jörg Hackermüllerمشاهده پروفایل

استاد

• Bioinformatics
• Omics Data Analysis
• Toxicology
• +۳ مورد دیگر

Prof. Dr. Jörg Hackermüller is a computational biologist with expertise in Omics data integration Toxicology Environmental risk assessment Non-coding RNA biology . He serves as Head of the Department of Computational Biology and Chemistry at the Helmholtz Centre for Environmental Research (UFZ) since 2024 and holds a Professorship at the Faculty of Mathematics and Computer Science at Leipzig University since 2021. His research focuses on Developing AI methods for chemical toxicity prediction Multi-omics integration for mechanistic toxicology Data standardization in environmental monitoring Non-coding RNAs as biomarkers in disease and toxicity and has produced 15+ recent publications spanning tools like multiGSEA and deepFPlearn+ . He collaborates with teams across UFZ Leipzig University Novartis Fraunhofer Institute and leads projects like InCeTo and SafePol , integrating exposome research with systems biology.

Kimberly Keil Stietzمشاهده پروفایل

استادیار

• Environmental Toxicology
• Neurotoxicology
• Urology
• +۴ مورد دیگر

Kimberly Keil Stietz is an Assistant Professor in the Department of Comparative Biosciences at the University of Wisconsin-Madison School of Veterinary Medicine. Her research focuses on environmental toxicology, neurotoxicology, and urology, particularly examining how developmental exposure to polychlorinated biphenyls (PCBs) affects urinary function. Education: B.S. in Biology, St. Norbert College (2010) Ph.D. in Comparative Biosciences, University of Wisconsin-Madison (2014) Postdoctoral research in neurotoxicology, University of California-Davis (2015-2019) Stietz's lab investigates the effects of environmental contaminants on the lower urinary tract, emphasizing PCB exposure during development. Using in vitro and in vivo mouse models, the lab studies disruptions in bladder epithelium organization, nerve fiber patterning, inflammation, and peripheral-central nervous system crosstalk. Key projects include analyzing PCB impacts on bladder barrier function, innervation patterns, inflammatory responses, and dorsal root ganglia signaling. Recent publications highlight her work on PCB effects across multiple domains: adult female bladder contractility (2023), prostatic collagen changes (2023), machine learning-aided metabolite analysis (2023, 2022), and developmental PCB exposure links to voiding physiology (2022). Her 2021 studies explored behavioral phenotypes in PCB-exposed mice, dendritic effects, and bladder inflammation, while 2019 work included host-microbe interactions and open-source uroflowmetry tools.

HO Han Kiatمشاهده پروفایل

دانشیار

• Chronic Liver Diseases
• Drug-Induced Liver Injury
• Nanomaterials in Medicine
• +۵ مورد دیگر

A/Prof HO Han Kiat is an Associate Professor in the Department of Pharmacy and Pharmaceutical Sciences at the National University of Singapore. His research focuses on chronic liver disease progression (from fatty liver to cancer) and drug-induced liver injury mechanisms. He explores nanomaterial applications in disease modification and drug delivery, using techniques like high-throughput sequencing and preclinical collaborations with clinicians. His work bridges cancer biology and toxicology, emphasizing clinical relevance through patient sample correlations. He teaches courses such as PR4207 Applied Pharmacokinetics & Toxicokinetics and FSC4203 Forensic Toxicology & Poisons. His lab’s vision involves developing molecular interventions for liver disorders through in vitro/vivo models. Notable interests include nanomaterial toxicity, hepatoprotective strategies, and cytokine profiles in cognitive impairment post-chemotherapy. Recent articles highlight studies on BDNF biomarkers, gold nanoparticle vascular targeting, and therapeutic hypothermia for hepatotoxicity. His research integrates genetic polymorphism analysis (e.g., CYP7A1) with drug metabolism studies, emphasizing personalized medicine approaches. HO’s work also addresses educational innovations in pharmacy curricula and assessment design, reflecting his dual focus on clinical research and pedagogy.

Jennifer Goldenمشاهده پروفایل

دانشیار

• Synthetic Medicinal Chemistry
• Antiviral Drug Development
• Antiparasitic Drug Discovery
• +۳ مورد دیگر

Jennifer Golden is an Associate Professor in the Department of Pharmaceutical Sciences at the School of Pharmacy , University of Wisconsin-Madison . Her research focuses on synthetic medicinal chemistry to develop novel antiviral and anti-parasitic agents for diseases like alphavirus infections and kinetoplastid parasites. The Golden Lab emphasizes chemical methodology development and structure-activity relationship analysis through collaborations assessing compound efficacy in cell and animal models . Research Projects Quinazolinone Rearrangement: Developing synthetic transformations for amidine formation and ring-fused scaffolds. Anti-Alphaviral Agents: Creating FDA-approved therapeutic candidates for mosquito-borne RNA viruses. Broad-Spectrum Antiparasitics: Optimizing compounds for malaria, African sleeping sickness, and leishmaniasis. Publications highlight her work on ML336 (anti-VEEV), quinazolinone derivatives , and collaborations with experts in high-throughput screening and structural biology . Her lab trains students in hit-to-lead optimization , regioselective synthesis , and medicinal chemistry tactics . Education: B.S. (1996) – Eastern Illinois University Ph.D. (2002) – University of Kansas Postdoctoral Research (2004) – Stanford University

• Cadmium Toxicology
• Environmental Pollutants
• Pharmacology
• +۵ مورد دیگر

Professor Walter C. Prozialeck is a distinguished academic at Midwestern University, serving in the Department of Pharmacology across multiple schools including the Chicago College of Osteopathic Medicine (CCOM), College of Pharmacy, College of Dental Medicine-Illinois, and College of Graduate Studies - Illinois. He holds a Ph.D. in Pharmacology from Thomas Jefferson University (1978) and a B.S. from Juniata College (1974). Dr. Prozialeck's research spans 35 years of cadmium toxicology, focusing on mechanisms of nephrotoxicity, microRNA expression, and biomarker development. He also investigates vancomycin pharmacokinetics and herbal medications like kratom and marijuana, contributing to drug policy discussions. His work has secured over $3.0 million in NIH funding. Recent publications highlight his expertise in cadmium-induced kidney injury biomarkers (e.g., Kim-1, cystatin C), microRNA alterations, and vascular toxicity. He has authored over 100 papers and book chapters. Career Achievement Award, Metals Specialty Section of Society of Toxicology (2021) Dr. Prozialeck teaches Pharmacology to medical, pharmacy, optometry, dental, and allied health students, and lectures in CME programs. He has held leadership roles including President of the Great Lakes Chapter of ASPET and Midwest Regional Chapter of the Society of Toxicology.

Srinivas Sridharمشاهده پروفایل

عضو هیئت علمی

• Nanomedicine
• Neurotechnology
• Drug Delivery
• +۷ مورد دیگر

Srinivas Sridhar is a University Distinguished Professor of Physics, Biomedical Engineering, and Chemical Engineering at Northeastern University, with a secondary appointment as Lecturer on Radiation Oncology at Harvard Medical School. He previously served as Vice Provost for Research at Northeastern University (2004–2008), overseeing its research portfolio. As an elected Fellow of the American Physical Society and the American Institute of Medical and Biological Engineering, his research spans nanomedicine, neurotechnology, drug delivery, and quantitative MRI, with over 450 publications and patents. He founded the Nanomedicine Innovation Center and directs major NIH/NSF programs like CaNCURE and IGERT, focusing on undergraduate and graduate training in nanomedicine, particularly for underrepresented communities. His research interests include Nanomedicine Neurotechnology Quantitative MRI Drug Delivery Systems Metamaterials and Nanophotonics Quantum Chaos Superconductivity . Recent work involves machine learning-enhanced diagnostics for glaucoma, engineered nanoparticles for BRCA-deficient cancers, and portable neuro-ophthalmic devices. His publications from 2025–2017 reflect interdisciplinary applications in oncology, neurology, and materials science, with a focus on therapeutic and diagnostic innovation. Scientific accolades include the 2016 Biomedical Engineering Society Diversity Award University Distinguished Professorship . As an educator and entrepreneur, he has trained over 120 researchers, developed first-of-their-kind nanomedicine courses, and founded companies commercializing technologies like QUTE-CE MRI. His lab leads projects on cancer nanomedicine, quantitative imaging, and nanoscale magnetism, supported by grants from NIH, NSF, DoD, and private foundations.

Alison Elderمشاهده پروفایل

دانشیار

• Toxicology of Inhaled Ultrafine Particles
• Engineered Nanomaterials
• Air Pollution and Neurodegeneration
• +۱۲ مورد دیگر

Alison Elder, Ph.D., is an Associate Professor in the Department of Environmental Medicine at the University of Rochester School of Medicine and Dentistry. She is affiliated with several research programs including the Environmental Health Sciences Center, the Inhalation Exposure Facility, the Toxicology Training Program (as Co-Director), the Lung Biology and Disease Program, and the Multidisciplinary Training in Pulmonary Research Program. Her research focuses on the toxicology of inhaled ultrafine particles (UFPs) and engineered nanomaterials, with implications for pulmonary, cardiovascular, and central nervous system health. Ph.D. in Environmental Toxicology, University of California, Irvine (1997) B.S. in Chemistry, Chatham College (1992) Post-doctoral Fellow, Department of Environmental Medicine, University of Rochester (1997–2000) Dr. Elder’s research centers on the health impacts of airborne particulate matter, particularly how age, co-pollutants, and health status influence responses to inhaled particles. Her work explores the translocation of particles to extrapulmonary tissues, including the brain, and their role in neurodegenerative diseases like Alzheimer’s. She investigates mechanisms such as oxidative stress, inflammation, and glymphatic dysfunction. Her lab also studies airborne micro- and nanoplastics, focusing on exposure characterization and health implications. Her recent publications span topics including Alzheimer’s disease models, glymphatic impairment, nanoparticle dissolution, and diesel exhaust effects on lung barriers. These works emphasize particle-induced inflammation, neurotoxicity, and the intersection of environmental exposure with neurological outcomes. Young Investigator Award, Society of Toxicology (2009) Cornerstone Alumna Award, Chatham University (2007) Graduate Student Fellowship, U.S. EPA (1995–1996) College Chemistry Award, Society for Analytical Chemists of Pittsburgh (1992) Dr. Elder mentors graduate students in toxicology and has trained numerous postdoctoral fellows and technicians. She leads an active research laboratory funded by NIH and DOD, investigating air pollution’s role in brain health and military burn pit exposures. Her collaborative research includes work with experts in neuroscience, materials science, and environmental engineering. She is also involved in national workshops on nanomaterial risk assessment and children’s environmental health. She leads the Elder Lab, which conducts studies on air pollution and Alzheimer’s disease, characterizes airborne micro- and nanoplastics, and develops models for nanoparticle toxicity. The lab uses advanced techniques in particle characterization, animal modeling, and cellular assays to assess health risks.

• Fish Physiology
• Ecotoxicology
• Nanotoxicology
• +۴ مورد دیگر

Matteo Minghetti is an Associate Professor in the Department of Integrative Biology at Oklahoma State University's College of Arts and Sciences. His research focuses on fish physiology and ecotoxicology, particularly investigating the toxicity and bioavailability of metals and emerging contaminants such as nanoparticles and microplastics in fish. He leads a research group that collaborates with environmental engineers and geologists to uncover toxicity mechanisms and develop alternative testing methods to reduce animal use in toxicity testing. Dr. Minghetti obtained his PhD in Ecotoxicology from the University of Stirling in the United Kingdom in 2009 and completed his Laurea in Biotechnology from the University of Bologna, Italy in 2003. His postdoctoral training included research positions at the Swiss Federal Institute of Aquatic Science and Technology (Eawag), King's College London, and the University of Stirling, where he studied transcriptional regulation of lipid metabolism, primary gill cultures for environmental biomonitoring, and mechanisms of toxicity of metal nanoparticles. His research program centers on developing and utilizing in vitro fish cell models (particularly RTgutGC and RTgill-W1 cell lines) to study metal toxicity, nanoparticle effects, microplastic interactions, and contaminant bioavailability. He has secured multiple significant grants including NIH, NSF, Alltech, and Alternatives Research & Development Foundation funding to support this work. His publications demonstrate a consistent focus on understanding how environmental conditions, such as chloride concentration, luminal composition, and plastic aging, influence metal speciation, bioavailability, and toxicity in fish systems. Dr. Minghetti actively mentors students through undergraduate research, Niblack Research Scholars program, and graduate thesis/dissertation supervision. He teaches courses including Physiology, Environmental Physiology, and Chronicles of Extreme Physiology, emphasizing both human and comparative animal systems.